X0306 4 2020-05-15 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2020-05-15 4 S 0 10 276.35 D 35282 D Common Stock 2020-05-15 4 S 0 17 279.93 D 35265 D Common Stock 2020-05-15 4 S 0 12 280.71 D 35253 D Common Stock 2020-05-15 4 S 0 10 283.58 D 35243 D Common Stock 2020-05-15 4 S 0 10 285.00 D 35233 D Common Stock 2020-05-15 4 S 0 21 286.41 D 35212 D Common Stock 2020-05-15 4 S 0 24 287.62 D 35188 D Common Stock 2020-05-15 4 S 0 9 288.35 D 35179 D Common Stock 140 I 401(k) Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $279.93 (range $279.38 to $280.31). Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $280.71 (range $280.41 to $280.86). Open market sales reported on this line occurred at a weighted average price of $286.41 (range $286.16 to $287.04). Open market sales reported on this line occurred at a weighted average price of $287.62 (range $287.21 to $287.99). Open market sales reported on this line occurred at a weighted average price of $288.35 (range $288.23 to $288.43). /s/ Sabrina Yohai, Attorney-in-Fact 2020-05-19